Clinical Trials Logo
  1. Home
  2. Adenocarcinoma of the Lung
  3. NCT01218516

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Adenocarcinoma of the Lung Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum-Containing Doublet in Chemotherapy-Naive Subjects With Stage IV Adenocarcinoma of the Lung (FLAIR)

Clinical Trial Summary

The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed followed by farletuzumab or placebo on investigator-assessed progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or definitive clinical disease progression (eg, new occurrence of positive fluid cytology) in chemotherapy naive participants with folate receptoralpha (FRA)-expressing Stage IV adenocarcinoma of the lung.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01218516
Study type Interventional
Source Morphotek
Contact
Status Completed
Phase Phase 2
Start date June 27, 2011
Completion date November 1, 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Phase 2
Recruiting NCT02288026 - Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer N/A
Recruiting NCT02239432 - Telomere Biology in Early Adenocarcinoma of the Lung N/A
Completed NCT00087412 - S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Phase 2
Completed NCT00049543 - Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Phase 3
Terminated NCT01707823 - Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer Early Phase 1
Completed NCT00002852 - Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Phase 3
Completed NCT04046614 - Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology Phase 1/Phase 2
Completed NCT00040794 - Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Phase 2
Terminated NCT00042835 - Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer Phase 1
Active, not recruiting NCT01345851 - Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery N/A
Withdrawn NCT02059967 - Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC Phase 1
Completed NCT00005838 - Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Phase 3
Terminated NCT02715102 - Circulating Tumor DNA in Patients at High Risk for Lung Cancer N/A
Terminated NCT00369551 - Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT00118144 - Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Phase 2
Completed NCT00020709 - Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Phase 3
Withdrawn NCT02466568 - Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Phase 1/Phase 2
Completed NCT01557959 - Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Phase 2
Completed NCT00118183 - Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Phase 2